[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:multiple-sclerosis":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":309,"states":314},"Multiple Sclerosis",196,150,[8,16,23,30,36,43,50,56,62,68,74,80,86,92,98,104,110,116,122,128,134,140,146,152,158,164,170,176,181,187,192,198,203,209,214,220,226,232,238,245,251,257,263,269,274,280,286,292,298,304],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07225504","A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis",[12],"Phase 3","RECRUITING","2026-08-26T02:18:31.944757Z","2026-07-19T19:36:05.066837Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06170970","Solriamfetol for the Treatment of Multiple Sclerosis Fatigue",[20],"Phase 2","2026-08-26T02:17:44.240289Z","2026-07-05T05:32:16.745839Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT07660601","Gait Adaptation Study",[27],"Early Phase 1","2026-08-26T02:19:07.104270Z","2026-07-05T03:45:20.257077Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT07615725","Dry Needling in Multiple Sclerosis",[],"2026-08-26T02:17:05.172421Z","2026-05-29T15:36:40.233918Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT07614321","Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis",[40],"Phase 4","2026-08-26T02:17:48.768272Z","2026-05-29T15:36:40.233801Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":48,"content_modified":49},"NCT05704361","A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis",[47],"Phase 1","2026-08-26T02:18:39.640967Z","2026-05-05T02:43:29.694400Z",{"nct_id":51,"title":52,"phases":53,"status":13,"updated_at":54,"content_modified":55},"NCT05958381","Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation",[],"2026-08-26T02:17:40.683658Z","2026-05-05T02:43:29.666427Z",{"nct_id":57,"title":58,"phases":59,"status":13,"updated_at":60,"content_modified":61},"NCT06901687","Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS)",[20],"2026-08-26T02:15:48.613507Z","2026-05-05T02:43:29.666348Z",{"nct_id":63,"title":64,"phases":65,"status":13,"updated_at":66,"content_modified":67},"NCT06341023","Functional Balance Intervention in Multiple Sclerosis",[],"2026-08-26T02:17:14.343713Z","2026-05-05T02:43:29.586095Z",{"nct_id":69,"title":70,"phases":71,"status":13,"updated_at":72,"content_modified":73},"NCT06552611","Non-invasive Electrical Spinal Cord Stimulation To Restore Upper Extremity Function in Multiple Sclerosis",[47],"2026-08-26T02:16:24.135291Z","2026-05-05T02:43:29.539905Z",{"nct_id":75,"title":76,"phases":77,"status":13,"updated_at":78,"content_modified":79},"NCT07389590","Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis",[40],"2026-08-26T02:18:12.612955Z","2026-05-05T02:43:29.395443Z",{"nct_id":81,"title":82,"phases":83,"status":13,"updated_at":84,"content_modified":85},"NCT06270641","Increasing Physical Activity for Adults With Multiple Sclerosis (MS)",[],"2026-08-26T02:15:04.877798Z","2026-05-05T02:43:29.283584Z",{"nct_id":87,"title":88,"phases":89,"status":13,"updated_at":90,"content_modified":91},"NCT06197685","A Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in Multiple Sclerosis",[],"2026-08-26T02:16:59.895916Z","2026-05-05T02:43:29.156745Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT06434571","Comparing Telehealth-Delivered CBT-I to Web-Based CBT-I to Enhance Sleep, Reduce Fatigue, and Promote Neuroprotection",[20],"2026-08-26T02:17:34.833510Z","2026-05-05T02:43:29.017841Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT06608797","Testing the Feasibility of Computer-based Cognitive Training in Individuals with Multiple Sclerosis Living in the Community",[],"2026-08-26T02:16:15.345907Z","2026-05-05T02:43:28.984950Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT05285891","Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis",[40],"2026-08-26T02:17:20.511551Z","2026-05-05T02:43:28.961132Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT02784210","Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques",[20],"2026-08-26T02:17:00.709807Z","2026-05-05T02:43:28.875963Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT07225361","Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis",[40],"2026-08-26T02:17:29.353236Z","2026-05-05T02:43:28.837038Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT06408259","Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis",[12],"2026-08-26T02:15:59.318403Z","2026-05-05T02:43:28.822857Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT06220201","A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)",[47],"2026-08-03T03:02:58.488119Z","2026-05-05T02:43:28.742927Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT05964829","Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis",[],"2026-08-26T02:15:27.567165Z","2026-05-05T02:43:28.642517Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT06463743","Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)",[20],"2026-08-26T02:16:33.772093Z","2026-05-05T02:43:28.541561Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT07074886","A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)",[20],"2026-08-03T03:13:22.003666Z","2026-05-05T02:43:28.415420Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT07497399","Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis",[20],"2026-08-26T02:18:49.989941Z","2026-05-05T02:43:28.348152Z",{"nct_id":159,"title":160,"phases":161,"status":13,"updated_at":162,"content_modified":163},"NCT05735691","High-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis",[],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:28.347775Z",{"nct_id":165,"title":166,"phases":167,"status":13,"updated_at":168,"content_modified":169},"NCT06390930","Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS",[],"2026-08-26T02:15:47.754948Z","2026-05-05T02:43:28.289003Z",{"nct_id":171,"title":172,"phases":173,"status":13,"updated_at":174,"content_modified":175},"NCT07355387","Home Based Functional Balance Intervention for Multiple Sclerosis",[],"2026-08-26T02:18:52.966503Z","2026-05-05T02:43:28.112805Z",{"nct_id":177,"title":178,"phases":179,"status":13,"updated_at":48,"content_modified":180},"NCT07325292","Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis",[12],"2026-05-05T02:43:28.099074Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT06809192","Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue",[],"2026-08-26T02:19:29.119921Z","2026-05-05T02:43:27.953960Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":174,"content_modified":191},"NCT06529406","Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod",[40],"2026-05-05T02:43:27.951475Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":196,"content_modified":197},"NCT07224373","An Open-label Study of AZD0120 in Adults With Multiple Sclerosis",[47],"2026-08-26T02:17:51.502023Z","2026-05-05T02:43:27.923682Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":168,"content_modified":202},"NCT06428006","Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis",[20],"2026-05-05T02:43:27.809548Z",{"nct_id":204,"title":205,"phases":206,"status":13,"updated_at":207,"content_modified":208},"NCT06981013","Effects of Torso Weighting on Muscle Activation During Balance Tests in Individuals With and Without Multiple Sclerosis",[],"2026-08-26T02:16:02.918558Z","2026-05-05T02:43:27.805905Z",{"nct_id":210,"title":32,"phases":211,"status":13,"updated_at":212,"content_modified":213},"NCT06394310",[],"2026-08-26T02:16:20.336282Z","2026-05-05T02:43:27.612051Z",{"nct_id":215,"title":216,"phases":217,"status":13,"updated_at":218,"content_modified":219},"NCT06796504","The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study",[],"2026-08-26T02:18:18.766496Z","2026-05-05T02:43:27.481307Z",{"nct_id":221,"title":222,"phases":223,"status":13,"updated_at":224,"content_modified":225},"NCT06629428","Effects of Ublituximab on Motor Functions in Multiple Sclerosis",[27],"2026-08-26T02:18:46.948970Z","2026-05-05T02:43:27.449592Z",{"nct_id":227,"title":228,"phases":229,"status":13,"updated_at":230,"content_modified":231},"NCT06441617","Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis",[],"2026-08-26T02:15:20.225313Z","2026-05-05T02:43:27.406021Z",{"nct_id":233,"title":234,"phases":235,"status":13,"updated_at":236,"content_modified":237},"NCT06992115","A Study of the MIND Diet for Persons With Multiple Sclerosis",[],"2026-08-26T02:17:07.954622Z","2026-05-05T02:43:27.395572Z",{"nct_id":239,"title":240,"phases":241,"status":13,"updated_at":243,"content_modified":244},"NCT03109288","Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)",[242],"Phase 1\u002FPhase 2","2026-08-26T02:19:28.327680Z","2026-05-05T02:43:27.285897Z",{"nct_id":246,"title":247,"phases":248,"status":13,"updated_at":249,"content_modified":250},"NCT06138132","A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis",[47],"2026-08-26T02:16:29.226604Z","2026-05-05T02:43:27.264594Z",{"nct_id":252,"title":253,"phases":254,"status":13,"updated_at":255,"content_modified":256},"NCT05500963","Reducing Fatigue in People With Multiple Sclerosis by Treatment With TENS",[],"2026-08-26T02:16:51.982021Z","2026-05-05T02:43:27.264023Z",{"nct_id":258,"title":259,"phases":260,"status":13,"updated_at":261,"content_modified":262},"NCT06782490","A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity",[20],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:27.099056Z",{"nct_id":264,"title":265,"phases":266,"status":13,"updated_at":267,"content_modified":268},"NCT05051618","Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis",[],"2026-08-26T02:18:30.351130Z","2026-05-05T02:43:27.098547Z",{"nct_id":270,"title":271,"phases":272,"status":13,"updated_at":218,"content_modified":273},"NCT02521311","Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)",[20],"2026-05-05T02:43:26.955206Z",{"nct_id":275,"title":276,"phases":277,"status":13,"updated_at":278,"content_modified":279},"NCT07392879","Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients",[],"2026-08-26T02:19:19.975067Z","2026-05-05T02:43:26.947654Z",{"nct_id":281,"title":282,"phases":283,"status":13,"updated_at":284,"content_modified":285},"NCT06890923","Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis",[20],"2026-08-26T02:17:50.500039Z","2026-05-05T02:43:26.946760Z",{"nct_id":287,"title":288,"phases":289,"status":13,"updated_at":290,"content_modified":291},"NCT06495138","Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis",[],"2026-08-26T02:15:44.309045Z","2026-05-05T02:43:26.897082Z",{"nct_id":293,"title":294,"phases":295,"status":13,"updated_at":296,"content_modified":297},"NCT06554340","Vascular Mechanisms, Functional Outcomes, & Exercise Among Persons With Multiple Sclerosis With Hypertension",[],"2026-08-26T02:19:25.538428Z","2026-05-05T02:43:26.897057Z",{"nct_id":299,"title":300,"phases":301,"status":13,"updated_at":302,"content_modified":303},"NCT04047628","Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)",[12],"2026-08-26T02:19:10.436356Z","2026-05-05T02:43:26.769703Z",{"nct_id":305,"title":306,"phases":307,"status":13,"updated_at":249,"content_modified":308},"NCT07067463","A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis",[12],"2026-05-05T02:43:26.675429Z",[310],{"biomarker":311,"count":312,"slug":313},"X-linked Lymphoproliferative Syndrome 1",3,"x-linked-lymphoproliferative-syndrome-1",[315,319,323,327,331,335,339,342,346,349,353,357,360,364,368,371,375,378,382,385,389,393,397,400],{"state":316,"count":317,"slug":318},"California",38,"california",{"state":320,"count":321,"slug":322},"Illinois",33,"illinois",{"state":324,"count":325,"slug":326},"Massachusetts",32,"massachusetts",{"state":328,"count":329,"slug":330},"New York",29,"new-york",{"state":332,"count":333,"slug":334},"Maryland",25,"maryland",{"state":336,"count":337,"slug":338},"Ohio",22,"ohio",{"state":340,"count":337,"slug":341},"Texas","texas",{"state":343,"count":344,"slug":345},"Florida",21,"florida",{"state":347,"count":344,"slug":348},"Washington","washington",{"state":350,"count":351,"slug":352},"Colorado",18,"colorado",{"state":354,"count":355,"slug":356},"Michigan",16,"michigan",{"state":358,"count":355,"slug":359},"New Jersey","new-jersey",{"state":361,"count":362,"slug":363},"Pennsylvania",15,"pennsylvania",{"state":365,"count":366,"slug":367},"Georgia",14,"georgia",{"state":369,"count":366,"slug":370},"Wisconsin","wisconsin",{"state":372,"count":373,"slug":374},"Alabama",13,"alabama",{"state":376,"count":373,"slug":377},"Kansas","kansas",{"state":379,"count":380,"slug":381},"Missouri",12,"missouri",{"state":383,"count":380,"slug":384},"North Carolina","north-carolina",{"state":386,"count":387,"slug":388},"Tennessee",11,"tennessee",{"state":390,"count":391,"slug":392},"Connecticut",10,"connecticut",{"state":394,"count":395,"slug":396},"Arizona",9,"arizona",{"state":398,"count":395,"slug":399},"District of Columbia","district-of-columbia",{"state":401,"count":395,"slug":402},"Minnesota","minnesota"]